Literature DB >> 17452585

Quantitative objective markers for upper and lower motor neuron dysfunction in ALS.

H Mitsumoto1, A M Ulug, S L Pullman, C L Gooch, S Chan, M-X Tang, X Mao, A P Hays, A G Floyd, V Battista, J Montes, S Hayes, S Dashnaw, P Kaufmann, P H Gordon, J Hirsch, B Levin, L P Rowland, D C Shungu.   

Abstract

OBJECTIVE: To investigate the value of objective biomarkers for upper (UMN) and lower (LMN) motor neuron involvement in ALS.
METHODS: We prospectively studied 64 patients with ALS and its subsets using clinical measures, proton MR spectroscopic imaging ((1)H MRSI), diffusion tensor imaging, transcranial magnetic stimulation, and the motor unit number estimation (MUNE) at baseline and every 3 months for 15 months and compared them with control subjects.
RESULTS: (1)H MRSI measures of the primary motor cortex N-acetyl-aspartate (NAA) concentration were markedly reduced in ALS (p = 0.009) and all UMN syndromes combined (ALS, familial ALS [fALS], and primary lateral sclerosis; p = 0.03) vs control values. Central motor conduction time to the tibialis anterior was prolonged in ALS (p < 0.0005) and combined UMN syndromes (p = 0.001). MUNE was lower in ALS (p < 0.0005) and all LMN syndromes combined (ALS, fALS, and progressive muscular atrophy; p = 0.001) vs controls. All objective markers correlated well with the ALS Functional Rating Scale-Revised, finger and foot tapping, and strength testing, suggesting these markers related to disease activity. Regarding changes over time, MUNE changed rapidly, whereas neuroimaging markers changed more slowly and did not significantly differ from baseline.
CONCLUSIONS: (1)H MR spectroscopic imaging measures of the primary motor cortex N-acetyl-aspartate (NAA) concentration and ratio of NAA to creatine, central motor conduction time to the tibialis anterior, and motor unit number estimation significantly differed between ALS, its subsets, and control subjects, suggesting they have potential to provide insight into the pathobiology of these disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17452585     DOI: 10.1212/01.wnl.0000260065.57832.87

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  74 in total

Review 1.  Neuroimaging in amyotrophic lateral sclerosis.

Authors:  Sumei Wang; Elias R Melhem; Harish Poptani; John H Woo
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Advances in the application of MRI to amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Michel Modo
Journal:  Expert Opin Med Diagn       Date:  2010-11

3.  Motor neuron disease: progressive muscular atrophy in the ALS spectrum.

Authors:  Nicholas J Maragakis
Journal:  Nat Rev Neurol       Date:  2010-04       Impact factor: 42.937

Review 4.  The present and the future of neuroimaging in amyotrophic lateral sclerosis.

Authors:  F Agosta; A Chiò; M Cosottini; N De Stefano; A Falini; M Mascalchi; M A Rocca; V Silani; G Tedeschi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825

5.  Diffusion tensor imaging of basal ganglia and thalamus in amyotrophic lateral sclerosis.

Authors:  Khema R Sharma; Sulaiman Sheriff; Andrew Maudsley; Varan Govind
Journal:  J Neuroimaging       Date:  2012-01-24       Impact factor: 2.486

6.  Structural hallmarks of amyotrophic lateral sclerosis progression revealed by probabilistic fiber tractography.

Authors:  Robert Steinbach; Kristian Loewe; Joern Kaufmann; Judith Machts; Katja Kollewe; Susanne Petri; Reinhard Dengler; Hans-Jochen Heinze; Stefan Vielhaber; Mircea Ariel Schoenfeld; Christian Michael Stoppel
Journal:  J Neurol       Date:  2015-07-10       Impact factor: 4.849

Review 7.  ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration.

Authors:  John M Ravits; Albert R La Spada
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910

8.  Multipoint incremental motor unit number estimation as an outcome measure in ALS.

Authors:  J M Shefner; M L Watson; L Simionescu; J B Caress; T M Burns; N J Maragakis; M Benatar; W S David; K R Sharma; S B Rutkove
Journal:  Neurology       Date:  2011-06-15       Impact factor: 9.910

Review 9.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

10.  Structural brain network imaging shows expanding disconnection of the motor system in amyotrophic lateral sclerosis.

Authors:  Esther Verstraete; Jan H Veldink; Leonard H van den Berg; Martijn P van den Heuvel
Journal:  Hum Brain Mapp       Date:  2013-03-01       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.